La catena delle opzioni mostra i dati chiave delle opzioni azionarie di HCW Biologics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per HCW Biologics..

HCW Biologics (NASDAQ:HCWB) Azioni, Catena delle Opzioni

HCW Biologics

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

HCW Biologics Inc

Canaccord Genuity analyst Joseph Vafi maintains Globant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) with a Hold and maintains $205 price target.

News

Price Target

Analyst Ratings

GLOB

Canaccord Genuity Maintains Hold on Globant, Maintains $205 Price Target

Stifel analyst Nathan Jones downgrades Ingersoll Rand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>) from Buy to Hold and lowers the price target from $112 to $107.

Downgrades

Stifel Downgrades Ingersoll Rand to Hold, Lowers Price Target to $107

Canaccord Genuity analyst Sumant Kulkarni maintains GH Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) with a Buy and lowers the price target from $31 to $28.

GHRS

Canaccord Genuity Maintains Buy on GH Research, Lowers Price Target to $28

Stifel analyst Nathan Jones downgrades ESAB (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESAB#NYSE">ESAB</a>) from Buy to Hold and lowers the price target from $138 to $130.

ESAB

Stifel Downgrades ESAB to Hold, Lowers Price Target to $130

Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) shares have surged 12% to $46.80 in November, fueled by investor optimism following Donald Trump's presidential election win and the expectation of favorable economic policies for the <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">banking industry</a>. 
What To Know: Trump's agenda, including potential tax cuts and regulatory rollbacks, is anticipated to create a supportive environment for financial institutions. Lower corporate taxes would allow Bank of America to retain more earnings, which could be used to expand lending operations, return capital to shareholders, or invest in new technologies.
Trump's focus on deregulation, including easing restrictions under the Dodd-Frank Act, is another positive for Bank of America. Reduced compliance costs and increased operational flexibility would allow the bank to grow its retail and commercial lending segments more aggressively. This could translate into higher revenues, particularly as businesses seek financing to capitalize on economic growth.
Additionally, Trump's infrastructure spending plans may spur demand for corporate credit and advisory services, further bolstering Bank of America's revenues. 
Meanwhile, potential inflationary pressures under Trump's policies could keep interest rates higher, boosting the bank's net interest margins and profitability on loans.
Read Also: <a href="https://www.benzinga.com/24/11/42033047/us-stocks-likely-to-open-on-a-tentative-note-as-investors-gear-up-for-nvidia-retail-earnings-analyst-updates-sp-500-target-for-2025-says-market-is-expensive">US Stocks On Edge As Investors Gear Up For Nvidia, Retail Earnings</a>
<h2 class="wp-block-heading">Is BAC A Good Stock To Buy?</h2>
Wall Street analysts view Bank of America on the whole as an Outperform, given the history of coverage over the past three months. Keith Horowitz from Citigroup in Bank of America is the most optimistic, expecting a 17.39% rise in the stock in the coming year.
But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past 3 months, Bank of America rose 20.27%, which indicates that opinion improved on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which rose 0.68% over the past year.
A complete overview of how Wall Street views individual stocks is available <a href="https://www.benzinga.com/analyst-stock-ratings">here</a>, while real time updates on the latest analyst actions will be delivered via <a href="https://pro.benzinga.com">Benzinga PRO</a>. Try it for free.
BAC has a 52-week high of $46.84 and a 52-week low of $29.22.

What's Going On With Bank Of America (BAC) Shares

Canaccord Genuity analyst Joseph Vafi maintains CI&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CINT#NYSE">CINT</a>) with a Buy and raises the price target from $9 to $10.

CINT

Canaccord Genuity Maintains Buy on CI&T, Raises Price Target to $10

<a href="https://www.bloomberg.com/news/articles/2024-11-18/goldman-readies-plans-to-spin-out-its-digital-assets-platform?srnd=homepage-europe" title="https://www.bloomberg.com/news/articles/2024-11-18/goldman-readies-plans-to-spin-out-its-digital-assets-platform?srnd=homepage-europe">https://www.bloomberg.com/news/articles/2024-11-18/goldman-readies-plans-to-spin-out-its-digital-assets-platform?srnd=homepage-europe</a>

'Goldman Readies Plans To Spin-Out Its Digital Assets Platform' - Bloomberg News

Dear Whitestone REIT Board of Trustees:
MCB Real Estate ("MCB" or "we") delivered an attractive, fully-financed proposal to the Whitestone Board to acquire Whitestone for $15 per share in an all-cash transaction. Our proposal would maximize value to Whitestone's shareholders, delivering immediate and certain value in the form of a 14.5% premium to Whitestone's share price prior to our initial proposal on June 3, 2024, and a 61.8% premium to Whitestone's unaffected share price prior to the rumored Fortress proposal on October 26, 2023. We have made repeated efforts to engage with the Whitestone Board over the last several months, but each of those attempts has been summarily rebuffed. The Board's refusal to grant due diligence, engage in any meaningful discussions, or commence a strategic alternatives process is not consistent with its duties and indicates a boardroom culture of entrenchment.
While we continue to believe our proposal is the best path forward for shareholders, our attempts to engage have been rebuffed at every turn, so we are withdrawing our proposal to acquire Whitestone at this time.
This is not a decision taken lightly. We are disappointed and disturbed at the Board's intransigence, entrenchment and apparent self-interest. The Company's recent public comments make it painfully clear that the Board is not open-minded or even willing to give real consideration to opportunities to advance shareholders' best interests.
Just a few weeks ago, Whitestone defended its entrenched position with unsupported and unrealistic claims of Whitestone's greater hypothetical "intrinsic value." Notably, however, that value was not actually provided, proven or even explained. Whitestone also attempted to rationalize the Board's refusal to consider alternatives by relying on a period of stock price outperformance that was driven by multiple acquisition rumors and proposals, including ours, that inflated Whitestone's share price.
When pressed on whether the Board is open to opportunities to enhance value on Whitestone's third quarter 2024 earnings call, Whitestone CEO David Holeman falsely asserted that the Board is actively looking at strategic options. Further, he seemingly didn't even understand what such a process to maximize value would actually entail. When asked, he said:
"I would tell you that our board reviews the best things for shareholders all the time. So we are actively looking at what are the best ways to add value, what are the best ways to produce a return to our shareholders. So I think we are actively doing that just like we should, and so I'm not sure I'm clear with your question."
Given the Board's refusal to engage with us regarding our proposal or conduct a process to explore whether other parties may have an interest in transacting with Whitestone, Mr. Holeman's comments are at best a naïve sidestep to the question, and at worst a downright lie to shareholders.
We have heard from a number of other shareholders that they are supportive of a potential transaction and share our frustration with the Whitestone Board. We believe some of these shareholders have reached out to Whitestone directly to demand answers. Unfortunately, it appears that the Whitestone Board has ignored these concerns and refused to engage with them, just as it has consistently refused to engage with MCB.
As Whitestone's largest actively managed shareholder, with ownership of 4,690,000 shares representing 9.4% of Whitestone's common shares, we note the addition of Kristian M. Gathright and Donald A. Miller to the Whitestone Board. Ms. Gathright and Mr. Miller are two new and well-regarded independent trustees whom we hope will bring fresh perspective to the Board and ensure that the Whitestone Board acts in accordance with its fiduciary duties, including taking appropriate steps to maximize value for Whitestone shareholders.
The reputations and careers of these professionals, as well as the rest of the Board, are on the line, and we call on them to act in shareholders' best interests. We believe the inherent disadvantages of Whitestone as a standalone company, and the upside for shareholders from a well-run strategic review process, are obvious.
As we have said from the onset of this process, our interests are aligned with other Whitestone shareholders. Whitestone shareholders deserve a board that is committed to considering all opportunities to maximize value. If the Whitestone Board continues its pattern of delay and entrenchment, MCB believes the entire Board should be removed at the next annual meeting of shareholders.
While we are withdrawing our proposal at this time, we remain a significant shareholder of the company and will continue to consider all options available to MCB and other Whitestone shareholders to ensure that the Board upholds its responsibilities.
Sincerely,
/s/ P. David Bramble
P. David Bramble, Managing Partner

MCB Withdraws $15/Share Whitestone REIT Acquisition Proposal, Criticizes Board Entrenchment; Calls For Strategic Review To Maximize Shareholder Value

Canaccord Genuity analyst Sumant Kulkarni maintains ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) with a Buy and maintains $11 price target.

ATAI

Canaccord Genuity Maintains Buy on ATAI Life Sciences, Maintains $11 Price Target

GSAT

Globalstar To Transfer Stock Listing To Uplist On Nasdaq

Shengfeng Logistics holds a majority stake in the 51% in the Joint Venture

Contracts

SFWL

Shengfeng Development Forms Joint Venture With Fujian Fulai Aviation To Expand Low-Altitude Logistics Services

New travel platform for credit cardholders elevates U.S. Bank Travel Center with Booking.com as a preferred choice for cardholders
U.S. Bank has unveiled a new travel booking platform for U.S. Bank credit cardholders to reserve hotels, flights and rental cars. The U.S. Bank Travel Center with Booking.com, powered by Rocket Travel by Agoda, elevates travel planning and booking experiences through <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.rockettravel.com%2F&amp;esheet=54153685&amp;newsitemid=20241118909936&amp;lan=en-US&amp;anchor=Rocket+Travel+by+Agoda%26%238217%3Bs&amp;index=1&amp;md5=e28b5bb37260fc363dbe61c5d8b6399b">Rocket Travel by Agoda's</a> advanced booking technology and global online travel planning expertise and support.

BKNG

U.S. Bank Unveils A New Travel Booking Platform For U.S. Bank Credit Cardholders To Reserve Hotels, Flights And Rental Cars; U.S. Bank Travel Center With Booking.com

Stifel analyst Nathan Jones downgrades Curtiss-Wright (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>) from Buy to Hold and maintains the price target from $370 to $370.

Stifel Downgrades Curtiss-Wright to Hold, Maintains Price Target to $370

<ul>
<li>TSLA</li>
<li>NVDA</li>
<li>SMCI</li>
<li>INTC</li>
<li>RKLB</li>
<li>CORN</li>
<li>LOT</li>
<li>NFLX</li>
<li>LUNR</li>
<li>PLTR</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

CORN

INTC

LUNR

NFLX

NVDA

PLTR

RKLB

SMCI

TSLA

Top 10 Trending Stocks On WallStreetBets As Of November 18, 2024 (Via Swaggy Stocks)

Barclays analyst Ramsey El-Assal maintains Rackspace Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) with a Underweight and raises the price target from $1 to $2.

Barclays Maintains Underweight on Rackspace Tech, Raises Price Target to $2

Stifel analyst Nathan Jones downgrades Crane (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CR#NYSE">CR</a>) from Buy to Hold and maintains the price target from $176 to $176.

Stifel Downgrades Crane to Hold, Maintains Price Target to $176

HSBC analyst Yifeng Liu upgrades Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) from Hold to Buy and announces $58 price target.

Upgrades

MRNA

HSBC Upgrades Moderna to Buy, Announces $58 Price Target

Brands using Priceline Partner Solutions can now seamlessly offer Affirm's flexible and transparent payment options directly at checkout
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.affirm.com%2Fwhere-to-shop%3Futm_source%3Dcomms%26utm_medium%3Dpress%26utm_campaign%3Dnutribullet&amp;esheet=54153827&amp;newsitemid=20241118928993&amp;lan=en-US&amp;anchor=Affirm&amp;index=1&amp;md5=eabb427311e1b105c7d0a7bc38981105">Affirm</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>), the payment network that empowers consumers and helps merchants drive growth, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.priceline.com%2F%3Fvrid%3Dc013ab563bd80178537c8295793ef525&amp;esheet=54153827&amp;newsitemid=20241118928993&amp;lan=en-US&amp;anchor=Priceline&amp;index=2&amp;md5=d3e7178fa24f372079e662f98defdf25">Priceline</a>, a leader in online travel, today announced an expanded partnership. Through their deepened collaboration, Affirm is the pay-over-time provider for Priceline's B2B business, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpricelinepartnersolutions.com%2F&amp;esheet=54153827&amp;newsitemid=20241118928993&amp;lan=en-US&amp;anchor=Priceline+Partner+Solutions&amp;index=3&amp;md5=9e9a136726264508f6eaeb3d2b338e87">Priceline Partner Solutions</a>. Beginning immediately, Priceline Partner Solutions partner brands — which span industries such as airlines, cruise lines, car rentals, hotels, and more — can offer approved travelers the ability to book trips now and pay over time, directly through their own websites.

AFRM

Priceline Selects Affirm As Pay-Over-Time Provider For Priceline Partner Solutions

Barclays analyst Anthony Powell maintains Prologis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>) with a Overweight and raises the price target from $131 to $132.

Barclays Maintains Overweight on Prologis, Raises Price Target to $132

Earnings

CISS

C3is Inc. Q3 Revenues $9.3M vs $10.1M YoY, Adj. Net Income $300K

HCW Biologics reports Q2 results

Warning: HCWB is at high risk of performing badly

HCW Biologics reports Q3 results

HCW Biologics jumps on license agreement for immunotherapeutic product candidate

HCW Biologics (HCWB) and WY Biotech, a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell t...

HCW Biologics licenses proprietary preclinical molecule to WY Biotech

HCWB

Press Releases

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

HCW Biologics and WY Biotech Announce License Agreement  for Immunotherapeutic Product Candidate

AIM ImmunoTech

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aprea Therapeutics

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Ensysce Biosciences

Imunon

Immuron Limited - American Depositary Shares

Immuron

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Mustang Bio

Mainz Biomed

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NKGen Biotech

Nanoviricides

Onconetix

BiomX

PharmaCyte Biotech

Palatin Techs

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Senti Biosciences

Synlogic

Tenax Therapeutics

Turnstone Biologics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

Comments

HCW Biologics

HCW Biologics (HCWB) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO